GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teligent Inc (OTCPK:TLGTQ) » Definitions » EV-to-FCF

Teligent (Teligent) EV-to-FCF : -3.78 (As of May. 28, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Teligent EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Teligent's Enterprise Value is $94.37 Mil. Teligent's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2021 was $-24.93 Mil. Therefore, Teligent's EV-to-FCF for today is -3.78.

The historical rank and industry rank for Teligent's EV-to-FCF or its related term are showing as below:

TLGTQ's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.695
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), Teligent's stock price is $0.0002. Teligent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $-3.883. Therefore, Teligent's PE Ratio for today is At Loss.


Teligent EV-to-FCF Historical Data

The historical data trend for Teligent's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teligent EV-to-FCF Chart

Teligent Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.20 -7.20 -5.65 -7.30 -8.32

Teligent Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.22 -6.34 -8.32 -5.12 -5.78

Competitive Comparison of Teligent's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Teligent's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teligent's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teligent's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Teligent's EV-to-FCF falls into.



Teligent EV-to-FCF Calculation

Teligent's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=94.374/-24.934
=-3.78

Teligent's current Enterprise Value is $94.37 Mil.
Teligent's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teligent  (OTCPK:TLGTQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Teligent's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0002/-3.883
=At Loss

Teligent's share price for today is $0.0002.
Teligent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.883.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Teligent EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Teligent's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Teligent (Teligent) Business Description

Traded in Other Exchanges
N/A
Address
105 Lincoln Avenue, Buena, NJ, USA, 08310
Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.
Executives
Joseph Benesch officer: VP, Controller, PAO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
Alyssa Lozynski officer: Interim CFO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310
William S Marth director 236 GROVE STREET, WELLESLEY MA 02482
Philip K Yachmetz officer: EVP, Chief Legal Off, Corp Sec 501 LAFAYETTE AVE WYCKOFF NJ 07481
R Carter Pate director 5739 WORTHAM LANE, DALLAS TX 75252
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Carole Ben-maimon director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Sabatino Thomas J Jr director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
John E Celentano director C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Steven H Koehler director C/O THE MEDICINES CO, 5 SYLVAN WAY, PARSIPPANY NJ 07054
Keith James officer: Prin Acct Officer Controller 105 LINCOLN AVENUE BUENA NJ 08310
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Donald V Weir 10 percent owner SANDERS MORRIS HARRIS, 600 TRAVIS, HOUSTON TX 77002
Timothy B. Sawyer officer: CEO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310